{"id":8708,"date":"2026-02-10T10:57:40","date_gmt":"2026-02-10T09:57:40","guid":{"rendered":"https:\/\/www.isrec.ch\/?post_type=recherche&#038;p=8708"},"modified":"2026-04-21T09:59:06","modified_gmt":"2026-04-21T07:59:06","slug":"translational-radiopharmaceutical-sciences-laboratory-of-prof-margret-schottelius-chuv-helene-koch-unilchuv","status":"publish","type":"recherche","link":"https:\/\/www.isrec.ch\/en\/research\/translational-radiopharmaceutical-sciences-laboratory-of-prof-margret-schottelius-chuv-helene-koch-unilchuv\/","title":{"rendered":"<strong>Translational radiopharmaceutical sciences laboratory<\/strong> &#8211; Prof. Margret Schottelius (CHUV) and H\u00e9l\u00e8ne\u00a0Koch (UNIL\/CHUV)"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Improving\u00a0the efficacy of\u00a0PSMA-Targeted radioligand therapy via\u00a0radiosensitization strategies and combination treatments<\/strong><\/h2>\n\n\n<h5 class=\"s3\"><span class=\"s2\">T<\/span><span class=\"s2\">his<\/span><span class=\"s2\"> \u201callocated fund\u201d<\/span><span class=\"s2\">,<\/span> <span class=\"s2\">amounting to <\/span><span class=\"s2\">CHF 150\u2019000<\/span><span class=\"s2\">,<\/span> <span class=\"s2\">was <\/span><span class=\"s2\">awarded<\/span> <span class=\"s2\">to <\/span><span class=\"s2\">H\u00e9l\u00e8ne Koch <\/span><span class=\"s2\">for two years<\/span> <span class=\"s2\">in December 2025. <span class=\"s7\">Supported <\/span><span class=\"s7\">with the generous contribution of the LARDECO Foundation.<\/span><\/span><\/h5>\n\n<div class=\"wp-bootstrap-blocks-row row\">\n\t\n\n<div class=\"col-12 col-md-6\">\n\t\t\t\n\n<p>PSMA-targeted radioligand therapy (PSMA-RLT) has emerged as a cornerstone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). While landmark clinical trials have demonstrated significant survival benefits, treatment resistance remains a major limitation. Up to 30% of patients show primary resistance, and the majority of initial&nbsp;responders&nbsp;relapse within months, reflecting the profound adaptability of prostate cancer cells and the activation of compensatory&nbsp;radioresistance&nbsp;pathways.&nbsp;<\/p>\n\n\n\n<p>Preclinical and clinical studies have shown that inhibition of single resistance pathways can enhance the efficacy of PSMA-RLT, but complete and durable remissions have remained elusive.&nbsp;This project&nbsp;is designed to address this unmet need by systematically evaluating&nbsp;radiosensitization&nbsp;strategies that target complementary resistance mechanisms&nbsp;either individually or in combination. In a stepwise approach, we will employ xenograft models with robust endogenous PSMA expression, integrating survival studies with in-depth&nbsp;<em>ex vivo<\/em>analyses to characterize treatment-induced changes in tumor biology. Radiosensitizers, chosen among already clinically approved&nbsp;drugs,&nbsp;will be administered in clinically relevant dosing schemes to assess their capacity to relieve hypoxia, disrupt repair signaling, and destabilize pro-survival pathways. <\/p>\n\n\t<\/div>\n\n\n\n<div class=\"col-12 col-md-6\">\n\t\t\t\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"536\" height=\"868\" src=\"https:\/\/www.isrec.ch\/app\/uploads\/2026\/02\/Screenshot-2026-02-12-at-17.50.48-1.png\" alt=\"\" class=\"wp-image-8733\" srcset=\"https:\/\/www.isrec.ch\/app\/uploads\/2026\/02\/Screenshot-2026-02-12-at-17.50.48-1.png 536w, https:\/\/www.isrec.ch\/app\/uploads\/2026\/02\/Screenshot-2026-02-12-at-17.50.48-1-185x300.png 185w\" sizes=\"auto, (max-width: 536px) 100vw, 536px\" \/><\/figure>\n\n\t<\/div>\n\n<\/div>\n\n\n\n<p>Synergistic regimens will be identified through iterative testing&nbsp;<em>in vivo<\/em>,&nbsp;and subsequently validated in an immunocompetent allograft model, providing critical insight into both tumor-intrinsic and microenvironmental contributions to resistance. The anticipated outcome is a set of rational, mechanism-informed&nbsp;radiosensitization&nbsp;regimens that markedly enhance the durability of tumor control by PSMA-RLT.&nbsp;<\/p>\n\n\n\n<p>By integrating biological characterization, imaging biomarkers, and translational infrastructure, the project aims not only to improve treatment efficacy in prostate cancer but also to establish a generalizable framework for combination&nbsp;radiotheranostics. Clinically, this work is expected to extend survival and&nbsp;improve&nbsp;quality of life for patients with advanced prostate cancer, while reducing the need for late-line toxic therapies. The insights gained will provide the basis for early-phase clinical trials and may ultimately transform PSMA-RLT from a variably effective therapy into a precision-guided platform capable of overcoming&nbsp;radioresistance&nbsp;at its roots.<\/p>\n","protected":false},"featured_media":0,"template":"","cat-recherche":[83],"class_list":["post-8708","recherche","type-recherche","status-publish","hentry","cat-recherche-translational-research"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/recherche\/8708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/recherche"}],"about":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/types\/recherche"}],"wp:attachment":[{"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/media?parent=8708"}],"wp:term":[{"taxonomy":"cat-recherche","embeddable":true,"href":"https:\/\/www.isrec.ch\/en\/wp-json\/wp\/v2\/cat-recherche?post=8708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}